Replies to post #547189 on NorthWest Biotherapeutics Inc (NWBO)

[thermo]

At this point I think door number two is most likely:

1. LP sells her interest in Advent and holds her interest in NWBO. Sort of like a Cognate second bite at the apple.

2. NWBO is acquired by a large pharma and LP continues holding her Advent interest. Just a caveat, if my first name began with the letter "M" I would first propose a combo trial co-development agreement together with an acquisition right of first refusal. But skipping the co-dev arrangement and going straight for a buyout is not out of the question.

3. LP sells her interest in both NWBO and Advent, joins ihub and writes repetitive posts over many years on why trial endpoints can be changed after trial initiation, provided the company is blinded to the specific data determining the new endpoint statistics.